As the supply shortage of GlaxoSmithKline's shingles vaccine continues, the drugmaker is making plans to ramp up production at a quicker pace, according to Bio Process International.
The drugmaker's Shingrix vaccine is hard to find in most states across the U.S. due to a high demand.
While the ramp-up may not curb the shortage right away, the drugmaker said it expects the accelerated production to help ease the shortage in the coming years.
"Shingrix should be an important growth driver for a number of years as we continue to expand capacity. More specifically, over the next two to three years, we plan to increase our annual capacity to levels of doses in the high-teens millions and build further from there," Luke Miels, president of global pharmaceuticals at GSK, told Bio Process International.